Disc Medicine Presents Data From SAD Cohorts Of A Phase 1b Trial In Patients With Chronic Kidney Disease And Anemia At The 2024 American Society Of Nephrology Kidney Week
Portfolio Pulse from Benzinga Newsdesk
Disc Medicine, Inc. presented positive data from a Phase 1b trial of DISC-0974 in patients with chronic kidney disease and anemia, showing promising results in iron mobilization and hemoglobin increase.
October 25, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Disc Medicine presented positive Phase 1b trial data for DISC-0974, showing effective iron mobilization and hemoglobin increase in CKD patients, potentially boosting investor confidence.
The positive trial results for DISC-0974 in CKD patients are likely to boost investor confidence in Disc Medicine's pipeline, potentially leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100